Amarin Corp Plc (AMRN)

[sstyles]

We will know more based on the oral arguments. Reread GSK's response:

From the filing:
GSK presented substantial evidence Teva’s partial label was not a true section viii carve-out because it left in language that instructed infringement via the post-MI LVD indication.

See GSK's response here: https://fedcircuitblog.com/wp-content/uploads/2020/12/Glaxo_Response.pdf